Suzhou Ribo Life Science and Madrigal Pharmaceuticals have achieved the first candidate drug nomination milestone in their siRNA partnership targeting metabolic dysfunction-associated steatohepatitis (MASH). This milestone marks progress toward clinical studies, with IND-enabling studies set to begin immediately. The collaboration leverages Ribo's siRNA drug discovery and delivery expertise alongside Madrigal's clinical experience in MASH, aiming to develop new RNA-based therapies for liver diseases with high unmet medical needs.
Idaho Copper Corporation announced an $18 million public offering of common stock and warrants priced at $4.85 per share, with an additional 45-day option for over-allotments. The proceeds will fund an updated Preliminary Economic Assessment, initial...
The global neonatal infant care market, valued at $3.06 billion in 2025, is projected to grow to $5.59 billion by 2035 at a CAGR of 6.21%. Growth is driven by increasing preterm births and neonatal complications like respiratory disorders and jaundic...
The FDA has approved Casgevy, a gene therapy using CRISPR technology, for children aged 2 and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). This therapy modifies patients' own stem cells to increase fetal hemo...
Aave recorded its highest single-day growth in new Ethereum wallets since 2021, adding 1,806 new addresses on June 30. This surge coincides with Standard Chartered's bullish $3,500 price target for Aave's token, despite the bank lowering its Bitcoin ...
Bitcoin recently hit a 21-month low near $58.1K with weak engagement from large holders, while retail investors aggressively accumulate. This divergence, with whales distributing and smaller wallets buying, weakens market structure and raises the ris...
